UPSC-CMS 2021 - Pharmacology PYQs Practice Questions

Q: Consider the following in respect of Ormeloxifene : 1. It is a research product of Central Drug Research Institute, Lucknow 2. It is a steroidal compound 3. It is a potent antiestrogen with weak estrogenic properties 4. It does not inhibit ovulation Which of the above are correct ?

1, 3 and 4. ***1, 3 and 4*** - Ormeloxifene, also known as **Centchroman**, was developed by the **Central Drug Research Institute (CDRI), Lucknow**, making statement 1 **correct**. - It is a **selective estrogen receptor modulator (SERM)** that acts as a **potent antiestrogen** in the uterus and breast, with **weak estrogenic activity** in other tissues like bone, thus statement 3 is **correct**. - Ormeloxifene has a **unique mechanism** among contraceptives: it **does not inhibit ovulation**. Instead, it works by **preventing implantation** through endometrial changes and altering cervical mucus, making statement 4 **correct**. - Statement 2 is **incorrect** because Ormeloxifene is a **non-steroidal compound**, not a steroidal one. *1, 2 and 3* - This option is incorrect because statement 2, claiming Ormeloxifene is a **steroidal compound**, is false. Ormeloxifene is a **non-steroidal SERM**. - While statements 1 and 3 are correct, the inclusion of incorrect statement 2 makes this option wrong. *1 and 3 only* - While statements 1 and 3 are indeed correct, this option is **incomplete** as it excludes statement 4. - Statement 4 is also correct—Ormeloxifene **does not inhibit ovulation**, which is a key distinguishing feature of this contraceptive. *2, 3 and 4* - This option is incorrect because statement 2 is false—Ormeloxifene is **non-steroidal**, not steroidal. - Although statements 3 and 4 are correct, the inclusion of the false statement 2 makes this entire option incorrect. [Practice more Pharmacology PYQs on OnCourse]

Q: Which of the following drugs should be avoided in the first-line ART regimens because of its well recognized metabolic toxicities ?

Stavudine (d4T). ***Stavudine (d4T)*** - **Stavudine** is a **nucleoside reverse transcriptase inhibitor (NRTI)** that is well-known for its significant **metabolic toxicities**, including **lipoatrophy**, peripheral neuropathy, and lactic acidosis [1]. - Due to these severe side effects, it is no longer recommended for first-line ART regimens and its use is generally avoided. *Tenofovir (TDF)* - While Tenofovir (TDF) can cause **renal toxicity** and **bone mineral density loss** [2], it is generally considered a safer option than stavudine regarding severe metabolic toxicities like lipoatrophy. - TDF is commonly used in first-line ART regimens, often in combination with other drugs. *Zidovudine (AZT)* - **Zidovudine** is associated with side effects such as **bone marrow suppression** (leading to anemia and neutropenia), myopathy, and gastrointestinal upset, but not typically the severe metabolic toxicities seen with stavudine. - It is still used in some ART regimens, particularly for prevention of mother-to-child transmission. *Lamivudine (3TC)* - **Lamivudine** is generally well-tolerated with a favorable side effect profile, primarily mild gastrointestinal symptoms, and is rarely associated with significant metabolic toxicities. - It is a cornerstone drug in many first-line ART regimens due to its efficacy and safety. [Practice more Pharmacology PYQs on OnCourse]

Question 1

Consider the following in respect of Ormeloxifene :

1. It is a research product of Central Drug Research Institute, Lucknow
2. It is a steroidal compound
3. It is a potent antiestrogen with weak estrogenic properties
4. It does not inhibit ovulation Which of the above are correct ?

Accepted Answer

1, 3 and 4

Answer

1, 2 and 3

Answer

2, 3 and 4

Answer

1 and 3 only

Question 2

Which of the following drugs should be avoided in the first-line ART regimens because of its well recognized metabolic toxicities ?

Accepted Answer

Stavudine (d4T)

Answer

Tenofovir (TDF)

Answer

Zidovudine (AZT)

Answer

Lamivudine (3TC)

UPSC-CMS 2021 — Pharmacology